Immunic Receives Notice of Allowance for US Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
Portfolio Pulse from Benzinga Newsdesk
Immunic, Inc. (NASDAQ:IMUX), a biotech company focused on therapies for chronic inflammatory and autoimmune diseases, announced the receipt of a Notice of Allowance from the USPTO for a patent application covering dosing regimens of Vidofludimus Calcium in treating Multiple Sclerosis.
November 21, 2023 | 11:32 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunic, Inc. has received a Notice of Allowance for a patent application from the USPTO, which protects the dosing regimens of Vidofludimus Calcium for Multiple Sclerosis treatment.
The Notice of Allowance for the patent application is a positive regulatory development for Immunic, Inc. It provides intellectual property protection for Vidofludimus Calcium, potentially strengthening the company's market position in the treatment of Multiple Sclerosis. This could lead to increased investor confidence and a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100